Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors

Lynn G Feun, S. Wallace, D. J. Stewart, V. P. Chuang, W. K. Yung, M. E. Leavens, M. A. Burgess, Niramol Savaraj, R. S. Benjamin, S. E. Young

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Thirty-five patients with malignant brain tumors (23 with primary tumors and 12 with brain metastases) progressing after cranial irradiation ± chemotherapy received cisplatin, 60 to 120 mg/m2 into the internal carotid artery by a transfemoral approach. Courses of therapy were repeated every 4 weeks. Therapeutic evaluation was performed monthly using the CT scan of the brain and clinical neurologic examination. Thirty patients were evaluable for response. Of 20 evaluable patients with primary malignant brain tumors, 6 responded to therapy and 5 had stable disease. The median time to tumor progression for responding patients was 33 weeks, for stable patients 16 weeks, and 13 weeks for all patients. Five of 10 evaluable patients with brain metastases responded to intracarotid cisplatin, and 2 patients had stable disease. The estimated median time to progression for responding patients was 30+ weeks and 12+ weeks for patients with stable disease. Side-effects included seizures in 5 courses, mental agitation and motor restlessness in 1, and transient hemiparesis in 7. One patient may have had a drug-related death, and one patient appeared to develop encephalopathy after treatment. Five patients had clinical deterioration in vision; in two patients it was bilateral. Intracarotid cisplatin has definite activity in patients with malignant primary brain tumors and in patients with brain metastases. The recommended starting dose for intracarotid cisplatin is 60 to 75 mg/m2. At this dose level side effects are uncommon, but includes the risk of neurologic and retinal toxicity.

Original languageEnglish
Pages (from-to)794-799
Number of pages6
JournalCancer
Volume54
Issue number5
StatePublished - Oct 11 1984
Externally publishedYes

Fingerprint

Brain Neoplasms
Cisplatin
Therapeutics
Brain
Neoplasm Metastasis
Cranial Irradiation
Psychomotor Agitation
Neurologic Examination
Brain Diseases
Internal Carotid Artery
Paresis
Nervous System
Neoplasms
Seizures

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feun, L. G., Wallace, S., Stewart, D. J., Chuang, V. P., Yung, W. K., Leavens, M. E., ... Young, S. E. (1984). Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer, 54(5), 794-799.

Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. / Feun, Lynn G; Wallace, S.; Stewart, D. J.; Chuang, V. P.; Yung, W. K.; Leavens, M. E.; Burgess, M. A.; Savaraj, Niramol; Benjamin, R. S.; Young, S. E.

In: Cancer, Vol. 54, No. 5, 11.10.1984, p. 794-799.

Research output: Contribution to journalArticle

Feun, LG, Wallace, S, Stewart, DJ, Chuang, VP, Yung, WK, Leavens, ME, Burgess, MA, Savaraj, N, Benjamin, RS & Young, SE 1984, 'Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors', Cancer, vol. 54, no. 5, pp. 794-799.
Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WK, Leavens ME et al. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer. 1984 Oct 11;54(5):794-799.
Feun, Lynn G ; Wallace, S. ; Stewart, D. J. ; Chuang, V. P. ; Yung, W. K. ; Leavens, M. E. ; Burgess, M. A. ; Savaraj, Niramol ; Benjamin, R. S. ; Young, S. E. / Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. In: Cancer. 1984 ; Vol. 54, No. 5. pp. 794-799.
@article{6d27ac50763940419c958e3199ee76c8,
title = "Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors",
abstract = "Thirty-five patients with malignant brain tumors (23 with primary tumors and 12 with brain metastases) progressing after cranial irradiation ± chemotherapy received cisplatin, 60 to 120 mg/m2 into the internal carotid artery by a transfemoral approach. Courses of therapy were repeated every 4 weeks. Therapeutic evaluation was performed monthly using the CT scan of the brain and clinical neurologic examination. Thirty patients were evaluable for response. Of 20 evaluable patients with primary malignant brain tumors, 6 responded to therapy and 5 had stable disease. The median time to tumor progression for responding patients was 33 weeks, for stable patients 16 weeks, and 13 weeks for all patients. Five of 10 evaluable patients with brain metastases responded to intracarotid cisplatin, and 2 patients had stable disease. The estimated median time to progression for responding patients was 30+ weeks and 12+ weeks for patients with stable disease. Side-effects included seizures in 5 courses, mental agitation and motor restlessness in 1, and transient hemiparesis in 7. One patient may have had a drug-related death, and one patient appeared to develop encephalopathy after treatment. Five patients had clinical deterioration in vision; in two patients it was bilateral. Intracarotid cisplatin has definite activity in patients with malignant primary brain tumors and in patients with brain metastases. The recommended starting dose for intracarotid cisplatin is 60 to 75 mg/m2. At this dose level side effects are uncommon, but includes the risk of neurologic and retinal toxicity.",
author = "Feun, {Lynn G} and S. Wallace and Stewart, {D. J.} and Chuang, {V. P.} and Yung, {W. K.} and Leavens, {M. E.} and Burgess, {M. A.} and Niramol Savaraj and Benjamin, {R. S.} and Young, {S. E.}",
year = "1984",
month = "10",
day = "11",
language = "English",
volume = "54",
pages = "794--799",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors

AU - Feun, Lynn G

AU - Wallace, S.

AU - Stewart, D. J.

AU - Chuang, V. P.

AU - Yung, W. K.

AU - Leavens, M. E.

AU - Burgess, M. A.

AU - Savaraj, Niramol

AU - Benjamin, R. S.

AU - Young, S. E.

PY - 1984/10/11

Y1 - 1984/10/11

N2 - Thirty-five patients with malignant brain tumors (23 with primary tumors and 12 with brain metastases) progressing after cranial irradiation ± chemotherapy received cisplatin, 60 to 120 mg/m2 into the internal carotid artery by a transfemoral approach. Courses of therapy were repeated every 4 weeks. Therapeutic evaluation was performed monthly using the CT scan of the brain and clinical neurologic examination. Thirty patients were evaluable for response. Of 20 evaluable patients with primary malignant brain tumors, 6 responded to therapy and 5 had stable disease. The median time to tumor progression for responding patients was 33 weeks, for stable patients 16 weeks, and 13 weeks for all patients. Five of 10 evaluable patients with brain metastases responded to intracarotid cisplatin, and 2 patients had stable disease. The estimated median time to progression for responding patients was 30+ weeks and 12+ weeks for patients with stable disease. Side-effects included seizures in 5 courses, mental agitation and motor restlessness in 1, and transient hemiparesis in 7. One patient may have had a drug-related death, and one patient appeared to develop encephalopathy after treatment. Five patients had clinical deterioration in vision; in two patients it was bilateral. Intracarotid cisplatin has definite activity in patients with malignant primary brain tumors and in patients with brain metastases. The recommended starting dose for intracarotid cisplatin is 60 to 75 mg/m2. At this dose level side effects are uncommon, but includes the risk of neurologic and retinal toxicity.

AB - Thirty-five patients with malignant brain tumors (23 with primary tumors and 12 with brain metastases) progressing after cranial irradiation ± chemotherapy received cisplatin, 60 to 120 mg/m2 into the internal carotid artery by a transfemoral approach. Courses of therapy were repeated every 4 weeks. Therapeutic evaluation was performed monthly using the CT scan of the brain and clinical neurologic examination. Thirty patients were evaluable for response. Of 20 evaluable patients with primary malignant brain tumors, 6 responded to therapy and 5 had stable disease. The median time to tumor progression for responding patients was 33 weeks, for stable patients 16 weeks, and 13 weeks for all patients. Five of 10 evaluable patients with brain metastases responded to intracarotid cisplatin, and 2 patients had stable disease. The estimated median time to progression for responding patients was 30+ weeks and 12+ weeks for patients with stable disease. Side-effects included seizures in 5 courses, mental agitation and motor restlessness in 1, and transient hemiparesis in 7. One patient may have had a drug-related death, and one patient appeared to develop encephalopathy after treatment. Five patients had clinical deterioration in vision; in two patients it was bilateral. Intracarotid cisplatin has definite activity in patients with malignant primary brain tumors and in patients with brain metastases. The recommended starting dose for intracarotid cisplatin is 60 to 75 mg/m2. At this dose level side effects are uncommon, but includes the risk of neurologic and retinal toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0021194323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021194323&partnerID=8YFLogxK

M3 - Article

C2 - 6331626

AN - SCOPUS:0021194323

VL - 54

SP - 794

EP - 799

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -